• ARQT

Arcutis Biotherapeutics CFO sells shares worth over $110,000

Arcutis Biotherapeutics' CFO sold shares amid significant growth and developments related to its psoriasis drug ZORYVE, while analysts maintain a positive outlook on the company's prospects.